View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 15, 2021updated 22 Nov 2021 1:05pm

Sanofi concludes acquisition of Translate Bio for $3.2bn

Sanofi expects the deal to be vital for its mRNA Center of Excellence to unravel mRNA vaccines’ potential.

Sanofi has concluded the acquisition of messenger RNA (mRNA) therapies company, Translate Bio, for $38 per share in cash, representing a total equity value of nearly $3.2bn, on a fully diluted basis.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

Last month, Sanofi signed a definitive agreement to acquire all outstanding shares of Translate Bio.

The takeover will expedite Sanofi’s efforts to create novel vaccines and treatments leveraging mRNA technology.

Furthermore, the deal supports Sanofi’s mRNA Center of Excellence, which plans to explore the potential of advanced mRNA vaccines and other key areas, including immunology, oncology and rare diseases.

With the acquisition, Translate Bio will continue as a surviving corporation and work as an indirect, fully owned unit of Sanofi.

Sanofi and Translate Bio signed a partnership and exclusive licence agreement in June 2018 to develop mRNA vaccines. The deal was expanded last year to address existing and future infectious diseases.

Two mRNA vaccine clinical trials are currently underway as part of the alliance.

Phase I/II trial of a Covid-19 vaccine is ongoing with results due in the third quarter of this year.

Another Phase I trial of an mRNA seasonal influenza vaccine is underway with results anticipated in the fourth quarter.

In the therapeutic segment, Translate Bio has a pipeline of early-stage assets for cystic fibrosis and other rare pulmonary diseases.

Furthermore, Translate Bio is conducting discovery activities in diseases impacting the liver. Its MRT platform may be used for several classes of therapies, including therapeutic antibodies or vaccines for fields such as oncology.

For the deal, Morgan Stanley served as the exclusive financial advisor to Sanofi while Weil, Gotshal & Manges was the legal counsel.

Centerview Partners was the lead financial advisor to Translate Bio and Paul, Weiss, Rifkind, Wharton & Garrison served as the legal counsel.

Sanofi noted that its recent acquisition of Tidal Therapeutics boosted the company’s mRNA research expertise in immuno-oncology as well as inflammatory diseases.

Tidal was acquired by Sanofi in a deal totalling approximately $470m in April.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology